Literature DB >> 3513567

Oral folic acid versus placebo in the treatment of males with the fragile X syndrome.

R J Hagerman, A W Jackson, A Levitas, M Braden, P McBogg, M Kemper, L McGavran, R Berry, I Matus, P J Hagerman.   

Abstract

A double-blind, crossover study of a 10 mg folic acid per day (vs. placebo) treatment was carried out in 25 fra(X) males (ages 1-31 years). Each treatment period lasted 6 months. Before, during and after the study, the patients were assessed blindly with psychological, language and behavioral evaluations, and parent or caretaker reports were collected. Standardized testing did not show statistically significant changes in the group as a whole; psychological testing demonstrated a statistically significant improvement on folic acid in the prepubertal males. After uncoding, caretaker or parent reports also demonstrated behavioral improvements in the prepubertal males while being treated with folic acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513567     DOI: 10.1002/ajmg.1320230119

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

Review 1.  Medical genetics.

Authors:  M Super
Journal:  Postgrad Med J       Date:  1991-07       Impact factor: 2.401

2.  Fragile X syndrome.

Authors:  J Turk
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

Review 3.  Fragile X syndrome.

Authors:  E Wiebe; A Wiebe
Journal:  Can Fam Physician       Date:  1994-02       Impact factor: 3.275

4.  Outcome measures for clinical trials in fragile X syndrome.

Authors:  Elizabeth Berry-Kravis; David Hessl; Leonard Abbeduto; Allan L Reiss; Andrea Beckel-Mitchener; Tiina K Urv
Journal:  J Dev Behav Pediatr       Date:  2013-09       Impact factor: 2.225

Review 5.  Treatments for fragile X syndrome: a closer look at the data.

Authors:  Scott S Hall
Journal:  Dev Disabil Res Rev       Date:  2009

Review 6.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.

Authors:  Aurore Curie; Kathy Yang; Irving Kirsch; Randy L Gollub; Vincent des Portes; Ted J Kaptchuk; Karin B Jensen
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

8.  Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers.

Authors:  Jonathan Polussa; Andrea Schneider; Randi Hagerman
Journal:  Brain Disord Ther       Date:  2014

Review 9.  Fragile X Premutation: Medications, Therapy and Lifestyle Advice.

Authors:  Deepika Kour Sodhi; Randi Hagerman
Journal:  Pharmgenomics Pers Med       Date:  2021-12-29

Review 10.  Systematic review of pharmacological treatments in fragile X syndrome.

Authors:  Jose-Ramon Rueda; Javier Ballesteros; Maria-Isabel Tejada
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.